Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norepinephrine + L-NAME
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Intraperitoneal
01
Overview
A combination of norepinephrine (a catecholamine vasopressor) and L-NAME (N-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor). This combination is primarily used in research settings to study vascular function, blood pressure regulation, and the interplay between adrenergic and nitric oxide pathways. Norepinephrine acts predominantly on α-adrenergic receptors to increase blood pressure, while L-NAME blocks nitric oxide production, leading to vasoconstriction and hypertension.
- Other names
- noradrenaline + L-NAME
02
Targets
ADRA1 (Alpha-1 adrenergic receptor family)ADRB1 (β1)NOS1 (nNOS)
Beyond the preview
Go deeper on norepinephrine + L-NAME.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norepinephrine + L-NAME.